Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
204 hedge funds and large institutions have $2.44B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2018 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 69 increasing their positions, 62 reducing their positions, and 34 closing their positions.
111% more call options, than puts
Call options by funds: $16M | Put options by funds: $7.56M
21% more capital invested
Capital invested by funds: $2.02B → $2.44B (+$422M)
12% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 34
11% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 62
1% more funds holding
Funds holding: 201 → 204 (+3)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$36.6M |
| 2 |
JP Morgan Chase
New York
|
+$28.6M |
| 3 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
+$27.5M |
| 4 |
Renaissance Technologies
New York
|
+$25.9M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$14.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$49.6M |
| 2 |
AC
Armistice Capital
New York
|
-$21.9M |
| 3 |
BC
Broadfin Capital
New York
|
-$18.7M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$18.6M |
| 5 |
Millennium Management
New York
|
-$15.6M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ZDA
226
Zweig-DiMenna Associates
New York
| – | -$156K | -11,000 | Closed |
|
|
PA
227
Profund Advisors
Bethesda,
Maryland
| – | -$153K | -10,745 | Closed |
|
|
IWM
228
IHT Wealth Management
Chicago,
Illinois
| – | -$71K | -5,150 | Closed |
|
|
SWP
229
Stratos Wealth Partners
Beachwood,
Ohio
| – | -$39K | -2,750 | Closed |
|
|
PHK
230
Point72 Hong Kong
Hong Kong
| – | -$20K | -1,377 | Closed |
|
|
BCM
231
Brasada Capital Management
Houston,
Texas
| – | -$14K | -1,000 | Closed |
|
|
FPFS
232
First Personal Financial Services
Charlotte,
North Carolina
| – | -$12K | -867 | Closed |
|
|
KF
233
Krilogy Financial
St. Louis,
Missouri
| – | -$6K | -400 | Closed |
|
|
PS
234
Portfolio Solutions
Royal Oak,
Michigan
| – | -$4K | -300 | Closed |
|
235
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$2K | -114 | Closed |
|
|
ML
236
McAdam LLC
Philadelphia,
Pennsylvania
| – | -$1K | -66 | Closed |
|
|
IA
237
IFP Advisors
Tampa,
Florida
| – | +$274 | +18 | New |
|
HZNP Hedge Fund Activity: Q2 2018 in Review
204 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q2 2018, worth a combined $2.44B — up 21% from $2.02B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new HZNP positions and 34 closed out — a net gain of 4 holders — while 69 added to existing stakes and 62 trimmed.
The largest buyer was Eagle Asset Management, opening a new position worth an estimated $36.6M. The largest seller was Scopia Capital Management, cutting an estimated $49.6M.
- 204 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q2 2018, up from 201 in Q1 2018.
- Funds reported $2.44B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q2 2018, up 21% quarter-over-quarter.
- 38 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q2 2018 and 34 closed out, a net change of +4 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q2 2018 was Eagle Asset Management, an estimated $36.6M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q2 2018 was Scopia Capital Management, an estimated $49.6M sold.
Based on aggregated 13F filings for Q2 2018.